Arcturus Therapeutics Holdings (ARCT) Operating Expenses (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Operating Expenses data on file, last reported at -$2.0 million in Q1 2026.

• Quarterly Operating Expenses fell 104.26% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.7 million (down 90.78% YoY) and the FY2025 annual result came in at -$10.5 million, down 104.22% from the prior year.
• Operating Expenses climbed to -$2.0 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $259.3 million in Q4 2024 to a low of -$3.9 million in Q2 2024.
• A 5-year average of $52.6 million and a median of $49.2 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses tumbled 105.93% — and 2025, when it soared 1120.9%.
• Tracing ARCT's Operating Expenses over 5 years: stood at $38.8 million in 2022, then advanced by 26.48% to $49.1 million in 2023, then surged by 427.85% to $259.3 million in 2024, then tumbled by 100.86% to -$2.2 million in 2025, then climbed by 11.71% to -$2.0 million in 2026.
• The last three Operating Expenses figures came in at -$2.0 million (Q1 2026), -$2.2 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.